Quest Diagnostics Incorporated revised consolidated earnings guidance for the full year of 2022. For the year, the company now expects net revenues to be in the range of $9.50 billion to $9.75 billion and reported diluted EPS to be in the range of $8.24 to $8.64, the prior guidance of Net revenues to be in the range of $9.2 billion to $9.5 billion and Reported diluted EPS to be in the range of $7.88 to $8.38.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
134.3 USD | -0.86% | +4.53% | -2.63% |
Apr. 25 | Labcorp beats quarterly estimates on strong testing demand | RE |
Apr. 24 | Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.63% | 14.92B | |
-14.92% | 84.68B | |
+13.30% | 81.12B | |
+10.92% | 29.4B | |
-12.71% | 16.73B | |
-3.06% | 16.36B | |
-3.97% | 11.66B | |
-1.42% | 11.72B | |
-31.75% | 11.77B | |
+27.44% | 11.71B |
- Stock Market
- Equities
- DGX Stock
- News Quest Diagnostics Incorporated
- Quest Diagnostics Incorporated Revises Consolidated Earnings Guidance for the Full Year of 2022